Endometriosis Trial: Study of NBI-56418 in Endometriosis

Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.

Timeline

Start

2005-04

Primary completion

2006-06

Completion

2006-06

Drugs

Indications